Xeris Biopharma Holdings Inc (NASDAQ:XERS) delivered a fourth-quarter earnings report that surpassed analyst expectations on both the top and bottom lines, capping off what management termed a "transformational year." The company's financial performance and ambitious guidance for 2026 appear to have resonated positively with investors, as evidenced by a significant pre-market surge in the stock price.
Earnings and Revenue Performance Versus Estimates
The biopharmaceutical company reported robust growth for the fourth quarter ended December 31, 2025. A key focus for investors was how these results stacked up against Wall Street's projections.
- Revenue: Xeris reported total Q4 revenue of $85.8 million. This exceeded the analyst consensus estimate of approximately $84.0 million.
- Earnings Per Share (EPS): The company reported non-GAAP diluted EPS of $0.06 for the quarter. This outperformed the analyst estimate of $0.0449.
This double beat marks a continuation of strong execution, with the company attributing the growth primarily to surging demand for its Cushing’s syndrome drug, Recorlev. For the full year 2025, total revenue reached $291.8 million, a 44% increase over the prior year.
Market Reaction and Price Action
The market's immediate reaction to the earnings release and forward guidance has been decidedly positive. Prior to the market open, XERS shares experienced a significant upward move of over 10%. This pre-market gain suggests investors are rewarding the company for not only exceeding quarterly expectations but also for providing a confident and growth-oriented outlook for the coming year.
This positive momentum stands in contrast to the stock's performance over recent weeks, where it had seen declines. The earnings report appears to have acted as a catalyst, reversing near-term negative sentiment.
Key Highlights from the Quarterly Report
Beyond the headline numbers, the earnings release outlined several critical developments for Xeris:
- Record Recorlev Growth: The standout performer was Recorlev, with net revenue soaring 100% year-over-year in Q4 to $45.3 million. For the full year, Recorlev revenue more than doubled, reaching $139.3 million.
- Portfolio Stability: The company's other commercial products, Gvoke (for severe hypoglycemia) and Keveyis (for primary periodic paralysis), also posted year-over-year revenue increases in the quarter of 6% and 15%, respectively.
- Path to Profitability: Xeris reported a net income of $11.1 million for Q4 2025, a substantial improvement from a net loss of $5.1 million in the same period last year. Full-year 2025 also resulted in a net income of $0.6 million, compared to a significant loss in 2024.
- Strong Balance Sheet: The company ended the year with $111.0 million in cash and cash equivalents, up from $71.6 million at the end of 2024, providing financial flexibility.
2026 Outlook Versus Analyst Expectations
Management provided detailed financial guidance for the full year 2026, projecting continued rapid growth. The company expects total revenue to range between $375 million and $390 million, which would represent more than 30% growth at the midpoint.
This outlook is notably higher than the current analyst consensus sales estimate for 2026, which stands at approximately $375.5 million, placing the company's own guidance at or above the high end of Wall Street's expectations. The guidance anticipates increased investment, particularly in research and development for the Phase 3-ready asset XP-8121 (for hypothyroidism) and in commercial efforts for Recorlev, while still forecasting growth in Adjusted EBITDA.
For a detailed breakdown of future quarterly and annual estimates, you can review the latest analyst projections on the Xers Biopharma earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy, sell, or hold any security, or an endorsement of any investment strategy. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
